(Reuters) - LONDON, June 29 - Sanofi-Aventis is
withdrawing its application to sell obesity drug rimonabant --
its biggest new drug hope -- in the United States, dealing a
further blow to its pipeline hopes.
Friday's move comes two weeks after a U.S. advisory panel
said the medicine should not be approved in the world's largest
drugs market because it may increase suicidal thinking and
depression.
Read more at Reuters.com Government Filings News
withdrawing its application to sell obesity drug rimonabant --
its biggest new drug hope -- in the United States, dealing a
further blow to its pipeline hopes.
Friday's move comes two weeks after a U.S. advisory panel
said the medicine should not be approved in the world's largest
drugs market because it may increase suicidal thinking and
depression.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment